ERBB2 and breast carcinoma: In other words, neoadjuvant treatment of HER2-positive breast cancer should lead to a more prominent improvement in prognosis compared to adjuvant chemotherapy with the same drug than neoadjuvant treatment of other breast cancer subtype, if pCR were a factor independently influencing a favorable prognosis.